8-K: TuHURA Biosciences and Kineta Stockholders Approve Merger, Paving Way for Combination

TuHURA Biosciences, Inc. and Kineta, Inc. stockholders have overwhelmingly approved all proposals related to their proposed merger, including an increase in authorized shares and reincorporation to Delaware, signaling the imminent closing of the transaction.

Summary

• TuHURA Biosciences, Inc. (TuHURA) and Kineta, Inc. (Kineta) stockholders approved all proposals related to their proposed merger on June 23, 2025.
• TuHURA's Special Meeting in Lieu of an Annual Meeting of Stockholders had a quorum of 29,134,982 shares present or by proxy, representing at least one-third of voting power as of May 15, 2025.
• Proposal No. 1, to amend the Articles of Incorporation to increase the number of authorized shares of TuHURA Common Stock from 75 million to 200 million shares, was approved with 28,531,894 votes For, 568,157 Against, and 34,930 Abstentions.
• Proposal No. 2, to approve the reincorporation of TuHURA from Nevada to Delaware, was approved with 23,703,577 votes For, 73,058 Against, 8,289 Abstentions, and 5,350,058 Broker Non-Votes.
• Proposal No. 3, to elect six director nominees (James Bianco, M.D., James Manuso, Ph.D., MBA, Alan List, M.D., George Ng, Robert E. Hoffman, and Craig Tendler, M.D.) to service until the 2026 annual meeting, was approved, with each nominee receiving over 21 million votes For.
• Proposal No. 4, to approve, on a non-binding advisory basis, the compensation for named executive officers, was approved with 21,009,852 votes For, 2,759,302 Against, and 15,764 Abstentions.
• Proposal No. 5, to ratify the appointment of Cherry Bekaert LLP as TuHURA's independent registered public accounting firm for fiscal year ending December 31, 2025, was approved with 28,867,309 votes For, 247,821 Against, and 19,851 Abstentions.
• Kineta stockholders also approved the proposed merger at their Special Meeting held on June 23, 2025.
• The parties anticipate that the Mergers will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.

Sentiment

Score: 8

Explanation: The document reports successful stockholder approvals for a significant merger, indicating progress towards a strategic combination. All key proposals passed with strong support, which is a positive signal for the transaction's completion and future prospects of the combined entity. The risks mentioned are standard for forward-looking statements in such filings and do not detract from the immediate positive outcome of the votes.

Positives

• All proposals presented to TuHURA stockholders were approved by the requisite votes, including the critical authorized share increase and reincorporation to Delaware.
• Kineta stockholders also approved the proposed merger, indicating mutual support for the transaction.
• The successful stockholder approvals pave the way for the imminent closing of the merger, subject to remaining conditions, advancing the strategic combination of the two companies.
• The merger aims to combine TuHURA's Phase 3 immune-oncology program (IFx-2.0 for Merkel Cell Carcinoma) with Kineta's clinical-stage immuno-oncology pipeline (KVA12123 in Phase 1/2 for advanced solid tumors), potentially creating a more robust and diversified pipeline.

Risks

• The completion of the Mergers on anticipated terms and timing, anticipated tax treatment, and unforeseen liabilities.
• Future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, pricing trends, future prospects, credit ratings, business and management strategies which may adversely affect TuHURA's business, financial condition, development programs, operating results and the price of its common stock.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market.
• Risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results.
• The risk that the conditions to the closing of the Merger are not satisfied.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement.
• Uncertainties as to the timing of the consummation of the Merger and the ability of each of TuHURA and Kineta to consummate the Merger.
• Risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger.
• Unexpected costs, charges or expenses resulting from the Merger.
• Competitive responses to the Merger.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger.

Future Outlook

TuHURA and Kineta expect to consummate the Mergers as soon as possible following the stockholder approvals, subject to the satisfaction or waiver of any remaining closing conditions under the Merger Agreement. The combined entity aims to develop novel immunotherapies to overcome resistance to cancer immunotherapy, leveraging TuHURA's Phase 3 IFx-2.0 and Kineta's clinical-stage KVA12123.

Management Comments

• TuHURA and Kineta issued a joint press release announcing the results of each company's respective special meetings of the stockholders.

Industry Context

The merger represents a strategic consolidation within the immuno-oncology biotechnology sector, aiming to combine complementary pipelines and expertise to address cancer immune resistance. This is a common strategy in biotech for companies to gain scale, diversify their pipeline, and potentially accelerate drug development by pooling resources and intellectual property, especially for clinical-stage companies. Kineta had previously announced a corporate restructuring and exploration of strategic alternatives, indicating this merger is a significant strategic move for them to enhance their market position and development capabilities.

Comparison to Industry Standards

• The document does not provide specific financial or clinical results for direct comparison to industry benchmarks or specific comparable companies/projects.
• The merger itself is a common strategic alternative for clinical-stage biotechnology companies, particularly those seeking to expand their pipeline or facing financial constraints, as Kineta was doing with its restructuring and search for alternatives.
• The approval of all merger-related proposals by stockholders is standard and necessary for such transactions to proceed, reflecting typical corporate governance processes for significant corporate events in the biotechnology industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The merger and related corporate actions (share increase, reincorporation) will significantly impact current shareholders of both TuHURA and Kineta, potentially leading to a combined entity with a broader pipeline and different risk/reward profile. The reincorporation to Delaware is often seen as beneficial for corporate governance and legal predictability.
• Employees: Kineta previously announced a significant workforce reduction in February 2024 as part of its restructuring. The merger could imply further integration or changes for employees of both companies post-merger as operations are combined.
• Customers/Patients: The merger aims to accelerate the development of novel immunotherapies, potentially benefiting future patients by bringing new treatments to market more efficiently.

Next Steps

• Consummate the Mergers as soon as possible, subject to the satisfaction or waiver of the remaining closing conditions under the Merger Agreement.
• TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Key Dates

Recommendation

Keywords

TuHURA Biosciences, Kineta, Merger, Stockholder Vote, 8-K, Biotechnology, Immuno-oncology, Cancer Immunotherapy, Corporate Governance, Share Authorization, Reincorporation, NASDAQ, Clinical Trial, IFx-2.0, KVA12123, Merkel Cell Carcinoma, Solid Tumors